NCT07028320View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

PHASE3CompletedINTERVENTIONAL

Enrollment

493

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

May 20, 2024

Conditions

Postmenopausal Women With Osteoporosis

Interventions

DRUG

SAL056 (56.5μg)

Administered by subcutaneous injection once a week during treatment phase

DRUG

Alendronate

70 mg tablet taken once a week during treatment phase

Trial Locations (1)

Unknown

Shanghai Sixth People's Hosptital, Shanghai

All Listed Sponsors

lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY

NCT07028320 - To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk | Biotech Hunter | Biotech Hunter